WO2024040187A3 - Sars-cov2 neutralizing single domain antibody constructs - Google Patents

Sars-cov2 neutralizing single domain antibody constructs Download PDF

Info

Publication number
WO2024040187A3
WO2024040187A3 PCT/US2023/072414 US2023072414W WO2024040187A3 WO 2024040187 A3 WO2024040187 A3 WO 2024040187A3 US 2023072414 W US2023072414 W US 2023072414W WO 2024040187 A3 WO2024040187 A3 WO 2024040187A3
Authority
WO
WIPO (PCT)
Prior art keywords
sars
cov2
single domain
domain antibody
antibody constructs
Prior art date
Application number
PCT/US2023/072414
Other languages
French (fr)
Other versions
WO2024040187A2 (en
Inventor
Aashish MANGLIK
Yue Wan
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of WO2024040187A2 publication Critical patent/WO2024040187A2/en
Publication of WO2024040187A3 publication Critical patent/WO2024040187A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Antibodies, including single-domain antibodies, that bind to SARS-CoV2 virus and methods of treatment using single-domain antibodies that bind to SARS-CoV2 virus are provided.
PCT/US2023/072414 2022-08-19 2023-08-17 Sars-cov2 neutralizing single domain antibody constructs WO2024040187A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263399617P 2022-08-19 2022-08-19
US63/399,617 2022-08-19

Publications (2)

Publication Number Publication Date
WO2024040187A2 WO2024040187A2 (en) 2024-02-22
WO2024040187A3 true WO2024040187A3 (en) 2024-05-02

Family

ID=89942302

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/072414 WO2024040187A2 (en) 2022-08-19 2023-08-17 Sars-cov2 neutralizing single domain antibody constructs

Country Status (1)

Country Link
WO (1) WO2024040187A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017196847A1 (en) * 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
WO2021231651A2 (en) * 2020-05-12 2021-11-18 The Regents Of The University Ofcalifornia Sars-cov2 neutralizing single domain antibody constructs
WO2022167815A1 (en) * 2021-02-04 2022-08-11 Rq Biotechnology Limited Antibodies
WO2022173670A1 (en) * 2021-02-09 2022-08-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies targeting the spike protein of coronaviruses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017196847A1 (en) * 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
WO2021231651A2 (en) * 2020-05-12 2021-11-18 The Regents Of The University Ofcalifornia Sars-cov2 neutralizing single domain antibody constructs
WO2022167815A1 (en) * 2021-02-04 2022-08-11 Rq Biotechnology Limited Antibodies
WO2022173670A1 (en) * 2021-02-09 2022-08-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies targeting the spike protein of coronaviruses

Also Published As

Publication number Publication date
WO2024040187A2 (en) 2024-02-22

Similar Documents

Publication Publication Date Title
MX2022014224A (en) Sars-cov2 neutralizing single domain antibody constructs.
MX2023003418A (en) Multispecific antigen-binding molecules and uses thereof.
WO2018237148A8 (en) Multispecific antibodies that target hiv gp120 and cd3
PH12020552221A1 (en) Anti-pd-1 antibodies and uses thereof
CA3156451A1 (en) Antibodies having specificity for nectin-4 and uses thereof
MD3353212T2 (en) Optimized anti-cd3 bispecific antibodies and uses thereof
EA201791961A1 (en) ANTIBODIES SPECIFIC TO CD47 AND PD-L1
JOP20200309A1 (en) Il-11 antibodies
PH12020552229A1 (en) Il-11ra antibodies
MX2022012083A (en) Multispecific antigen-binding molecules and uses thereof.
CR20220479A (en) Bispecific antigen binding molecules targeting ox40 and fap
WO2022031940A3 (en) Il28ra binding molecules and methods of use
MX2023004054A (en) Anti-dectin-1 antibodies and methods of use thereof.
MX2022014995A (en) Methods of treating iga nephropathy with an april binding antibody.
MX2023004275A (en) Anti-pd-1/cd40 bispecific antibodies and uses thereof.
MX2023002194A (en) Multi-specific antigen binding molecules targeting hiv and methods of use.
WO2022204713A3 (en) Antibodies to sars-cov-2
CR20230245A (en) Gucy2c binding molecules and uses thereof
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
WO2024040187A3 (en) Sars-cov2 neutralizing single domain antibody constructs
WO2021222595A3 (en) Multispecific antibodies targeting cd38 and epcam and uses thereof
WO2021058711A3 (en) Antigen binding proteins
MX2021009533A (en) Compositions and methods for using bispecific antibodies to bind complement and a target antigen.
WO2022238977A3 (en) Methods of treating dermatomyositis
TW202417477A (en) Antibodies that bind to multiple sarbecoviruses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23855690

Country of ref document: EP

Kind code of ref document: A2